Cytomask®, a Novel “Cis-Demasking” Cytokine Technology to Increase Therapeutic Index of Immunocytokines NANTES, France, November 7, 2025 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; ...
Tectonic Therapeutic, Inc., a clinical stage biotechnology company specializing in therapeutic proteins and antibodies that target G-protein coupled receptors (GPCRs), has announced its inclusion in ...
Approved JAK inhibitors such as ruxolitinib and fedratinib target the JH1 kinase domain, offering symptomatic relief but lacking selectivity for the mutant form. This non-selective inhibition disrupts ...
Werewolf Therapeutics (HOWL) shared preclinical data at the 2025 Society for Immunotherapy of Cancer’s 40th Annual Meeting, taking place November ...
WATERTOWN, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (TECX) (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of ...
The Festival of Biologics in Basel, Switzerland (October 17, 2024) The 16 th Annual Protein & Antibody Engineering Summit (PEGS) Europe Summit in Barcelona, Spain (November 7, 2024) The Antibody ...
In mice bearing poorly immunogenic EMT6 tumors, a sequential regimen of mWTX-330 (IL-12) followed by WTX-124 (IL-2) was well tolerated and demonstrated superior tumor-killing ability compared to ...
DUBLIN--(BUSINESS WIRE)--The "Molecular Switches As Therapeutic Targets, Drug Development, Drug Delivery Mechanism & Application By Indications Insight 2025" report has been added to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback